Fig. 4
From: Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program
Identification of anti-metastatic targets repressed by Ezh2. a Increased expression of Foxc1 predicted target genes coincides with reduced H3K27me3 enrichment status in Ezh2−/− versus Ezh2+/+ tumours. Right panel shows a comparison of H3K27me3 binding intensity between Ezh2+/+ and Ezh2−/− tumours for two known targets of FOXC1 activation, taken from the IGV browser. b Chord diagram of upregulated Foxc1 targets and their associated GO Biological Terms. The ChIP experiment is reflective of three different PyVmT cell lines. c Quantitative RT-PCR analysis of Foxc1 targets in PyVmT cells treated with GSK-126 (2 μM for 72 h) or DMSO (vehicle). Data is an average of experiments performed in three different PyVmT cell lines. *p < 0.05 (d) Chromatin immunoprecipitation of H3K27me3 or Foxc1 in the presence or absence of Ezh2-mediated H3K27me3 profiles. Three different PyVmT cell lines were treated with or without GSK-126 (2 μM, 72 h) or DMSO. Specific primers to detect binding by H3K27me3 and Foxc1 were designed. *p < 0.05, two tailed t-tests
